单位:[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Hubei, Peoples R China内科学系血液内科华中科技大学同济医学院附属同济医院[2]Chongqing Precis Biotech Co Ltd, Chongqing, Peoples R China
第一作者单位:[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
Hong Zhenya,Yang Zhi,Zhou Xiaoxi,et al.The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+B-ALL[J].BLOOD.2022,140:4625-4626.doi:10.1182/blood-2022-162134.
APA:
Hong, Zhenya,Yang, Zhi,Zhou, Xiaoxi,Wang, Gaoxiang,Zhou, Mi...&Huang, Liang.(2022).The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+B-ALL.BLOOD,140,
MLA:
Hong, Zhenya,et al."The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+B-ALL".BLOOD 140.(2022):4625-4626